疫苗在胶质母细胞瘤治疗中的新作用  

New role for vaccines in glioblastoma treatment

作　　者：李心玥 冯珊 孟坤 LI Xin-yue;FENG Shan;MENG Kun(SciTrials Medical Research,Wuhan 430000,Hubei Province,China;Wuhan Optics Valley Zhongyuan Pharmaceutical Co.,Ltd.,Wuhan 430000,Hubei Province,China)

机构地区：[1]先策医药科技(武汉)有限公司,湖北武汉430000 [2]武汉光谷中源药业有限公司,湖北武汉430000

出　　处：《中国临床药理学杂志》2023年第19期2871-2875,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：多形性胶质母细胞瘤是最具破坏性的脑肿瘤之一。目前常用的治疗方法,如化学疗法和放射疗法,无法阻止多形性胶质母细胞瘤(GBM)复发,还可能影响其他功能正常的细胞。治疗性mRNA疫苗是肿瘤免疫治疗的一种新方法。本文根据最新研究成果对肿瘤坏死因子相关凋亡诱导配体(TRAIL)疫苗、树突状细胞疫苗和病毒样颗粒(VLPs)疫苗接种抑制GBM进展的机制、安全性和有效性进行全面综述和分析,讨论了使用这些mRNA疫苗治疗GBM的可行性,为其他研究课题组进一步深入研究提供参考。Glioblastoma multiforme is one of the most devastating brain tumors.Current treatment methods,such as chemotherapy and radiation therapy,are unable to stop glioblastoma multiforme(GBM)recurrence and may also affect other functioning normal cells.Therapeutic mRNA vaccines have emerged as a novel approach to tumor immunotherapy.This article aims to provide a comprehensive review and analysis of the mechanisms,safety,and efficacy of administering tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)vaccines,dentric cell(DC)vaccines,and virus-like particless(VLPs)vaccines to restrain the progression of GBM according to the latest research findings.Further,the feasibility of using these mRNA vaccines for GBM treatment is discussed,providing a reference for further in-depth research by other research teams.

关 键 词：胶质母细胞瘤 树突状细胞疫苗 mRNA疫苗 病毒样颗粒疫苗 

分 类 号：R97[医药卫生—药品]